Embed Size (px)
Citation preview
www.ilts.org 1
ILTS.ORG
Immunosuppression in Liver TransplantationConsensus and Guidance Conference
February 9th-10thPark City, Utah, USA
INTERNATIONAL LIVER TRANSPLANTATION SOCIETY
www.ilts.org 2
ILTS HeadquartersK.I.T. Group GmbH
Association & Conference Management
Kurfürstendamm 71
10709 Berlin
Germany
Phone: +49 (0) 30 24603 349
Fax: +49 (0) 30 24603 200
www.ilts.org
Conference Venue:The Chateaux Deer Valley
7815 Royal Street East,
Park City, UT 84060,
USA
www.the-chateaux.com/
Session Room: Room Monet/Renoir
Registration: Please register online by 06 January 2017,
23:59 CET (GMT+2)
Should you require further assistance please don’t hesitate to
contact the ILTS Immuno Registration Department:
Hotline: +49 (0) 30 24603 410
Accommodation:All participants are responsible for their own accommodation.
The official conference hotel - The Chateaux Deer Valley
provides room availability for ILTS Immunosuppression
Conference participants.
To receive discounted room rates, please identify as conference
participants while booking your accommodation with The
Chateaux Deer Valley.
Reserve rooms at The Chateaux Deer Valley Hotel: Participants could call reservation line to make room
reservation.
Please identify as ILTS Immunosupporession Conference
participants while booking.
Reservation hotline: +1 800 453 1302
Reserve rooms in Park City:Participants could choose to stay in other hotels, please go to
Park City website for further information.
https://www.visitparkcity.com/places-to-stay/
Immunosuppression in Liver Transplantation Consensus and Guidance Conference
February 9th-10th 2017, Park City, Utah, USA
www.ilts.org 3
Immunosuppression in Liver Transplantation Consensus and Guidance Conference
February 9th-10th 2017, Park City, Utah, USA
Course Directors:Michael Charlton, MD, FRCP
Intermountain Medical Center
Murray, UT, USA
Josh Levitsky, MD, MS
Northwestern University
Chicago, IL, USA
Objectives:This conference will provide a detailed overview of the
current challenges and advances in immunosuppressive
therapy in the field of liver transplantation. International experts
will convene to focus on immunosuppression management
strategies and best practices in the consensus conference
format. The consensus conference proceedings will be used to
generate a Practice Guidelines manuscript for publication in
Transplantation. The conference will focus on three separate
areas:
• Mechanisms, and pharmacology of immunosuppressive
agents used in liver transplant recipients.
• Management of adverse effects of immunosuppressive
agents used in liver transplant recipients, including:
• Viral hepatitis, recurrence of non-viral primary liver disease,
renal toxicity, malignancy, metabolic syndrome
• Review emerging issues, including advances in biomarkers,
pharmacogenomics and approaches to early and
immunosuppression minimization.
Educational Goals: The overall goal of this course is to discuss the past, present
and future of immunosuppression therapy following liver
transplantation. It will focus on the most recent advances
and discuss selection of therapies based on diverse patient
phenotypes.
Learning objectives:• Understand the pros and cons of the use of different
maintenance and induction agents
• Understand immunosuppression management strategies in
special populations and disease states
• Learn the utility of therapeutic drug monitoring, drug
interactions and the potential for tailored dosing based on
genotypic/phenotypic patterns
• Learn about approaches to minimize the impact of long
term immunosuppression, including tailoring treatments
(including withdrawal) based on clinical features and
immune monitoring
www.ilts.org 4
Thursday, February 9th, 2017
Session One: Current State and Challenges Moderators: Michael Charlton (Intermountain Medical Center, Murray, UT, USA)
Josh Levitsky (Northwestern University, Evanston, IL, USA)
7:30 - 7:45 Introduction and Start of Session Michael Charlton (International Medical Center, Murray, UT, USA)
Josh Levitsky (Northwestern University, Evanston, IL, USA)
7:45 - 8:10 Current Induction and Maintenance Therapy in Liver Transplant Recipients Russell Wiesner (Mayo Clinic, Rochester, MN, USA)
8:10 - 8:15 Discussion
8:15 - 8:40 Posttransplant renal dysfunction: Mechanisms and strategies for avoidance
Faouzi Saliba (Hospital Paul Brousse, Villejuif, France)
8:40 - 8:45 Discussion
8:45 - 9:10 Immunosuppression and malignancy
John Roberts (University of California San Francisco, San Francisco, CA, USA)
9:10 - 9:15 Discussion
9:15 - 9:40 Special considerations in Pediatrics recipients
Manuel Rodriguez-Davalos (Yale New Haven Hospital, Connecticut, USA)
9:40 - 9:45 Discussion
10:00 - 17:00 BREAK
Immunosuppression in Liver Transplantation Consensus and Guidance Conference
February 9th-10th 2017, Park City, Utah, USA
www.ilts.org 5
Session Two: Immunosuppression Protocols Moderators: Kwan Man (University of Hong Kong, PR China)
Elizabeth Pomfret (Lahey Clinic, Burlington, MA, USA)
17:00 – 17:20 Prevention and Treatment of Acute and Chronic Rejection in the Modern Era John O’Grady (King’s College Hospital, London, UK)
17:20 – 17:25 Discussion
17:25 – 17:45 Diagnosis, Impact and Management of Antibody Mediated Rejection
Timucin Taner (Mayo Clinic, Rochester, MN, USA)
17:45 – 17:50 Discussion
17:50 –18:10 Immunosuppression: Impact on Obesity, Cardiovascular Disease and NASH
Philip Newsome (University of Birmingham, Birmingham, UK)
18:10 –18:15 Discussion
18:15 – 18:35 State of the Art Immunosuppression Monitoring
Kelly Birdwell (Vanderbilt University, Nashville, TN, USA)
18:35 – 18:40 Discussion
18:40 – 19:00 Immunosuppression Minimization and Withdrawal
Abraham Shaked (University of Pennsylvania, Philadelphia, PA, USA)
19:00 – 19:15 Discussion and Wrap-Up
Immunosuppression in Liver Transplantation Consensus and Guidance Conference
February 9th-10th 2017, Park City, Utah, USA
www.ilts.org 6
Friday, February 10th, 2017
Session Three: Working Groups for Immunosuppression Guidance Moderators: Patrizia Burra (Padova University, Padova, Italy)
Marina Berenguer (Hospital Universitario La Fe, Valencia, Spain)
8:00 – 10:00 Work Groups:
Initial and Maintenance Immunosuppression (type, dosing and monitoring)
Leads: Russell Wiesner (Mayo Clinic, Rochester, MN, USA)
John Fung (Cleveland Clinic, Cleveland, OH, USA)
Management of Acute, Chronic and Antibody Mediated Rejection
Leads: John O’Grady (King’s College Hospital, London, UK)
Timucin Taner (Mayo Clinic, Rochester, MN, USA)
Immunosuppression in Patients with Renal Insufficiency
Leads: Faouzi Saliba (Hospital Paul Brousse, Villejuif, France)
Elizabeth Pomfret (Lahey Clinic, Burlington, MA, USA)
Approach to Patients with Malignancy
Leads: John Roberts, University of California San Francisco, San Francisco, CA, USA)
James Trotter (Baylor University Medical Center, Dallas, TX, USA)
Immunosuppression in patients with Metabolic Syndrome
Leads: Mary Rinella (Northwestern University, Evanston, IL, USA)
Julie Heimbach (Mayo Clinic, Rochester, MN, USA)
Immunosuppression Minimization Strategies
Leads: Abraham Shaked (University of Pennsylvania, Philadelphia, PA, USA)
Marina Berenguer (Hospital Universitario La Fe, Valencia, Spain)
Immunosuppression Pediatric Recipients
Leads: Manuel Rodriguez-Davalos (Yale New Haven Hospital, Connecticut, USA)
Mohammadreza Rohaninejad (O‘Connor Hospital, San Jose, CA, USA)
10:00 - 17:00 BREAK
Immunosuppression in Liver Transplantation Consensus and Guidance Conference
February 9th-10th 2017, Park City, Utah, USA
www.ilts.org 7
Session Four: Report of Work GroupsModerators:
Kwan Man (University of Hong Kong, PR China)
Elizabeth Pomfret (Lahey Clinic)
17:00 – 17:20 Initial and Maintenance Immunosuppression (type, dosing and monitoring)
17:20 – 17:40 Management of Acute, Chronic and Antibody Mediated Rejection
17:40 – 18:00 Immunosuppression in Patients with Renal Insufficiency
18:00 – 18:20 Approach to Patients with Malignancy
18:20 – 18:40 Immunosuppression in patients with Metabolic Syndrome
18:40 – 19:00 Immunosuppression Minimization Strategies
19:00 – 19:15 Summary and Timetable for Production of Consensus and Guidance Document
Immunosuppression in Liver Transplantation Consensus and Guidance Conference
February 9th-10th 2017, Park City, Utah, USA
